Double-Action Lupus Drug Looks Good in Phase III Trial

(MedPage Today) — A novel drug for systemic lupus erythematosus (SLE) first developed in China, and approved there since 2021, did well enough in a new placebo-controlled phase III trial that approval in Western countries seems possible.
Called…